In addition, elucidation of nAChR structures, at the peripheral level, will serve to design and test drugs to treat diseases of the neuromuscular junction such as myasthenia gravis, CMS, Lambert–Eaton myasthenic syndrome, botulism, slow-channel congenital myasthenic syndrome, and fast-channel congenital myasthenic syndrome, among others. The gene discussed is CHRNA4; the disease is congenital myasthenic syndrome.